Chronic Migraine Clinical Trial
Official title:
Cannabis for the Prophylactic Treatment of Migraine: a Randomized Double-Blind Placebo-Controlled Clinical Trial
This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.
Migraine is a neurological disorder characterized by recurrent attacks of moderate to severe headache, often accompanied by sensory sensitivity and nausea. Migraine can be very disabling and often interferes with social and occupational functioning. Given the high prevalence of migraine and the significant burden it places on the individual and society, it is an important condition to study and manage optimally. This is especially true because current migraine treatments often result in only marginal improvement and are frequently associated with intolerable side effects. For this reason, there is a need for new migraine treatments. The endocannabinoid system is an important potential treatment target as it is involved in pain processing and overlaps with some mechanisms of migraine pathophysiology. Cannabis was legalized in Canada on October 17th, 2018. As a result, the consumption of cannabis products for migraine treatment may increase. However, at this time there is limited evidence for the safety and efficacy of cannabis for the treatment of migraine. As a result, there is a need for further study and research in this area. Thus, we propose a randomized, double-blind, placebo-controlled clinical trial to study cannabis (specifically cannabidiol) as a preventative therapy for patients with chronic migraine. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
| Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
| Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
| Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
| Completed |
NCT02514148 -
Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients
|
N/A | |
| Enrolling by invitation |
NCT02291380 -
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
|
Phase 3 | |
| Completed |
NCT02122237 -
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
|
Phase 3 | |
| Withdrawn |
NCT02122744 -
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
|
N/A | |
| Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
| Completed |
NCT01709708 -
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
|
Phase 4 | |
| Completed |
NCT01741246 -
Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging
|
N/A | |
| Completed |
NCT01090050 -
Treximet in the Treatment of Chronic Migraine
|
Phase 4 | |
| Recruiting |
NCT03507400 -
Introvision for Migraine and Headaches
|
N/A | |
| Completed |
NCT04161807 -
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
|
N/A | |
| Completed |
NCT03175263 -
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain
|
N/A | |
| Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
| Completed |
NCT01667250 -
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
|
N/A | |
| Completed |
NCT01700387 -
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
|
Phase 4 | |
| Not yet recruiting |
NCT01135784 -
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
|
Phase 2 | |
| Completed |
NCT00772031 -
NINDS CRC Chronic Migraine Treatment Trial
|
Phase 3 |